Mortality in Hepatitis C Virus–Infected Patients With a Diagnosis of AIDS in the Era of Combination Antiretroviral Therapy

Chronic hepatitis C increased mortality by approximately 50% in patients with Centers for Disease Control and Prevention–defined AIDS, despite the competing mortality risks in these patients. About 20% of the deaths were liver-related, suggesting that greater hepatitis C virus awareness and treatment could increase survival.

[1]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  D. Jabs,et al.  Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. , 1998, American journal of ophthalmology.

[3]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[4]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Holmes,et al.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[6]  M. Pfaller,et al.  Hepatitis C Virus Viremia in HIV‐Infected Individuals With Negative HCV Antibody Tests , 2002, Journal of acquired immune deficiency syndromes.

[7]  Keiji Fukuda,et al.  Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 , 2002 .

[8]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[10]  J. Bartlett,et al.  Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. , 2004, Clinical Infectious Diseases.

[11]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[12]  B. Walker,et al.  Pervasive Influence of Hepatitis C Virus on the Phenotype of Antiviral CD8+ T Cells1 , 2004, The Journal of Immunology.

[13]  G. Ippolito,et al.  Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Derek B Boothroyd,et al.  Effects of Hepatitis C Virus Coinfection on Survival in Veterans With HIV Treated With Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[15]  J. Kempen,et al.  Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. , 2005, Ophthalmology.

[16]  D. Boothroyd,et al.  HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations , 2005, AIDS.

[17]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[18]  R. Garfein,et al.  High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. , 2006, Drug and alcohol dependence.

[19]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[20]  A. Dolganiuc,et al.  Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-α and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection1 , 2006, The Journal of Immunology.

[21]  Mardge H. Cohen,et al.  Awareness of Hepatitis C Infection Among Women With and At Risk for HIV , 2007, Journal of General Internal Medicine.

[22]  J. Kempen,et al.  Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. , 2007, Ophthalmology.

[23]  V. Soriano,et al.  Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. , 2007, The Journal of infectious diseases.

[24]  J. Goedert,et al.  Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia , 2007, AIDS.

[25]  J. Kempen,et al.  Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. , 2007, Ophthalmology.

[26]  V. Soriano,et al.  Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. , 2007, AIDS research and human retroviruses.

[27]  S. Pol,et al.  Liver‐related mortality in human‐immunodeficiency‐virus‐infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) * , 2007, Journal of viral hepatitis.

[28]  V. Soriano,et al.  Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. , 2008, Journal of hepatology.

[29]  Anne M Johnson,et al.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population. , 2008, JAMA.

[30]  Rachel S Tocco,et al.  Public health impact of antiviral therapy for hepatitis C in the United States , 2009, Hepatology.

[31]  E. Ding,et al.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  C. Tural,et al.  Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus , 2009, Hepatology.

[33]  A. Mocroft,et al.  Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression , 2009, Journal of acquired immune deficiency syndromes.

[34]  O. Kirk,et al.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study , 2010, AIDS.

[35]  C. Larsen,et al.  Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. , 2010, Addiction.

[36]  Hong Yang,et al.  Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV–HCV coinfection before and after antiretroviral therapy , 2010, AIDS.

[37]  H. Krarup,et al.  Mortality in HIV‐infected injection drug users with active vs cleared hepatitis C virus‐infection: a population‐based cohort study , 2010, Journal of viral hepatitis.

[38]  S. Hohmann,et al.  The Economic Implications of Broader Sharing of Liver Allografts , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study , 2012, Journal of the International AIDS Society.